Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LUYE PHARMA GROUP LTD.

綠 葉 製 藥 集 團 有 限 公 司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

RECOMBINANT HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR ANTIBODY FUSION PROTEIN OPHTHALMIC

INJECTION BIOSIMILAR (LY09004)

CLINICAL TRIAL APPLICATION ACCEPTED IN CHINA

The board of directors (the ''Board'') of Luye Pharma Group Ltd. (the ''Company'', together with its subsidiaries, the ''Group'') is pleased to announce that, according to Shandong Boan Biological Technology Co., Ltd. (''Boan''), the clinical trial application of the biological antibody LY09004 has been accepted by National Medicine Product Administration (''NMPA'') in China.

ABOUT LY09004

LY09004 is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic Injection biosimilar indicated for neovascular (Wet) age-Related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with diabetic macular edema and visual impairment due to myopic choroidal neovascularisation (myopic CNV). The product was acquired from Boan. Please refer to the Company's announcement dated 21 December 2018 for information. According to public information, global sales of Eylea (a market comparable to LY09004) amounted to US$5,929 million in 2017, representing demand and growth potentials for the product.

ABOUT THE GROUP'S PIPELINE PRODUCTS

In addition to LY09004, the Group has three antibody products under different stages of clinical trial, including recombinant anti-VEGF humanised monoclonal antibody injection biosimilar (LY01008), which has entered phase III clinical trial, and Recombinant anti-RANKL fully human monoclonal antibody injection biosilimar (LY06006 and LY01011), which have entered phase I clinical trial. The Group will continue to invest in R&D in the field of biopharmaceuticals, to accelerate the deployment of the Group's innovative bio-pharmaceuticals, and further enrich the Group's product pipeline in the field of oncology, among others.

By Order of the Board LUYE PHARMA GROUP LTD.

Liu Dian Bo

Chairman

Hong Kong, 3 January 2019

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive director of the Company is Mr. SONG Rui Lin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.

Attachments

  • Original document
  • Permalink

Disclaimer

Luye Pharma Group Ltd. published this content on 03 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 03 January 2019 06:03:03 UTC